semaglutide achalasia Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes? A1C & Weight Results |

This study investigated whether semaglutide (SMG) can counteract the disruption to the gut-heart-metabolic axis and associated myocardial injury caused by obesity

The OASIS 1 and 2 trials compared the therapeutic efficacy and clinical safety profile of once-daily oral semaglutide 50 mg versus placebo on overweight and obese participants without T2DM and both with and withoutT2DM, respectively

Learn what happens, how to manage risks, and steps to avoid missing a dose again.

The concept of type 2 diabetes remission is evolving rapidly, and gaining wide public and professional interest, following demonstration that with substantial intentional weight loss almost nine in ten people with type 2 diabetes can reduce their HbA1c level below the diagnostic criterion (48 mmol/mol [6.5%]) without glucose-lowering medications, and improve all features of the metabolic syndrome